Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Product ID

Click to order products ascending

Display 15 Products per page

Teflaro
Read More
Teflaro (ceftaroline fosamil; Actavis/AstraZeneca/Dainippon Sumitomo Pharma) is a fifth-generation cephalosporin.
September 29, 2016
Find out more
TetraVax-DV
Read More
TetraVax-DV is a lyophilized, tetravalent, live-attenuated chimeric vaccine currently in Phase II/III development.
January 4, 2018
Find out more
Tivantinib
Read More
Tivantinib (ArQule/Daiichi Sankyo/Kyowa Hakko Kirin) is an orally available small molecule inhibitor of the hepatocyte growth factor (HGF) receptor, c-MET.
December 31, 2015
Find out more
Neratinib
Read More
Neratinib (Puma Biotechnology) is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptor (HER)1, HER2, HER4, and epidermal growth factor receptor kinases.
March 9, 2015
Find out more
Tivicay
Read More
Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.
June 28, 2019
Find out more
Neupro
Read More
Neupro (UCB/Otsuka) is a transdermal formulation of the non-ergoline dopamine receptor agonist rotigotine. Applied once daily, the patch allows continuous drug administration over 24 hours and avoids the fluctuation in dopaminergic stimulation resulting from numerous oral doses
June 21, 2018
Find out more
Tracleer
Read More
Actelion’s Tracleer (bosentan) was the first oral therapy to be developed specifically for the treatment of pulmonary arterial hypertension (PAH).
October 29, 2018
Find out more
Nouriast
Read More
Nouriast (istradefylline; Kyowa Hakko Kirin) is the first, and so far, the only adenosine A2a receptor antagonist to be approved for the treatment of Parkinson’s disease. It acts to decrease overactivity of the indirect pathway of the motor circuit that is present in Parkinson’s disease patients with low dopamine levels.
June 21, 2018
Find out more
Triumeq
Read More
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
June 28, 2019
Find out more
Tybost
Read More
Tybost (cobicistat; Gilead) is a boosting agent to be used in combination with protease inhibitors (PIs) as part of treatment regimens for HIV-1 infection.
December 11, 2015
Find out more
Tygacil
Read More
Tygacil (tigecycline; Pfizer) is the first of the glycylcycline class of antimicrobial agents. It targets and binds to the 30S subunit of the bacterial ribosomes.
June 19, 2015
Find out more
Tykerb
Read More
Tykerb (lapatinib; Novartis) is an orally available EGFR (epidermal growth factor receptor) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor.
March 9, 2015
Find out more
Peretinoin
Read More
Peretinoin (Kowa/Chugai Pharmaceutical) is a synthetic acyclic retinoid inhibitor of transforming growth factor alpha (TGF-alpha) and platelet-derived growth factor receptor (PDGFR). TGF-alpha induces epithelial development, and is closely involved in hepatocarcinogenesis.
December 31, 2015
Find out more
Ublituximab
Read More
Ublituximab (TG Therapeutics) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications.
January 31, 2019
Find out more
Prezista franchise
Read More
The Prezista franchise comprises the standalone protease inhibitor (PI) Prezista (darunavir; Johnson & Johnson) and the fixed-dose combination of Prezista and Tybost (cobicistat; Gilead), which is branded as Prezcobix in the US and Rezolsta in the EU.
June 28, 2019
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *